Live Breaking News & Updates on Ionis Pharmaceuticals Price Performance

Stay updated with breaking news from Ionis pharmaceuticals price performance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MQS Management LLC Takes Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

MQS Management LLC acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,547 shares of the company’s stock, valued at approximately $247,000. A number of other institutional investors and hedge […] ....

Sanfordc Bernstein , Tweedy Browne Co , Clearbridge Investments , Royal Bank , Exchange Commission , Ionis Pharmaceuticals Price Performance , Ionis Pharmaceuticals Inc , Mqs Management , Ionis Pharmaceuticals , First Trust Advisors , Vanguard Group Inc , Quarter For Ionis Pharmaceuticals , News Ratings For Ionis Pharmaceuticals Daily , Get Rating , Trust Advisors , Ionis Core , Visit Holdingschannel , Ionis Pharmaceuticals Daily , Nasdaq Ions , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Tweedy Browne Co LLC Acquires 818,148 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Tweedy Browne Co LLC raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 30.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,541,136 shares of the company’s stock after buying an additional 818,148 shares during the quarter. Ionis Pharmaceuticals accounts for […] ....

Almanack Investment Partners , Ionis Pharmaceuticals , Ionis Pharmaceuticals Price Performance , News Ratings For Ionis Pharmaceuticals Daily , Wipfli Financial Advisors , Ionis Pharmaceuticals Company Profile , Ionis Pharmaceuticals Inc , Quarter For Ionis Pharmaceuticals , Tweedy Browne Co , Guardian Wealth Advisors , Royal Bank , Get Rating , Financial Advisors , Wealth Advisors , Investment Partners , Quantbot Technologies , Ionis Core , Ionis Pharmaceuticals Daily , Nasdaq Ions , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of "Hold" from Analysts

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) has been assigned an average recommendation of “Hold” from the fourteen brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the […] ....

Sanfordc Bernstein , Eric Swayze , Piper Sandler , Tweedy Browne Co , News Ratings For Ionis Pharmaceuticals Daily , Securities Exchange Commission , Ionis Pharmaceuticals Price Performance , T Rowe Price Investment Management Inc , Vanguard Group Inc , Ionis Pharmaceuticals , Morgan Stanley , Clearbridge Investments , Ionis Pharmaceuticals Inc , Insider Activity At Ionis Pharmaceuticals , Analyst Recommendations For Ionis Pharmaceuticals , Get Rating , Marketbeat Ratings , Exchange Commission , Rowe Price Investment Management , Ionis Core , Ionis Pharmaceuticals Daily , Nasdaq Ions ,

AtonRa Partners Decreases Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

AtonRa Partners reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 21.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,875 shares of the company’s stock after selling 3,753 shares during the period. AtonRa Partners’ holdings in […] ....

Eric Swayze , Piper Sandler , Patrickr Oneil , Algert Global , Ionis Pharmaceuticals , Royal Bank , Quarter For Ionis Pharmaceuticals , Ionis Pharmaceuticals Price Performance , Exchange Commission , Morgan Stanley , News Ratings For Ionis Pharmaceuticals Daily , Gateway Investment Advisers , Ionis Pharmaceuticals Company Profile , Ionis Pharmaceuticals Inc , Tower Research Capital , Atonra Partners , Get Rating , Research Capital , Investment Advisers , Brookstone Capital Management , Capital Management , Ionis Core , Visit Holdingschannel , Ionis Pharmaceuticals Daily , Nasdaq Ions , Sec Filings ,

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Bard Financial Services Inc.

Bard Financial Services Inc. decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 38.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 53,925 shares of the company’s stock after selling 33,970 shares during the period. Bard Financial Services Inc.’s holdings […] ....

United States , Sanfordc Bernstein , Kokusai Asset Management Co , News Ratings For Ionis Pharmaceuticals Daily , Ionis Pharmaceuticals Inc , Quarter For Ionis Pharmaceuticals , Mitsubishi Ufj , Bard Financial Services Inc , Ionis Pharmaceuticals , Delphia United States Inc , Needham Company , Securities Exchange Commission , Insider Transactions At Ionis Pharmaceuticals , Ionis Pharmaceuticals Price Performance , Ionis Pharmaceuticals Company Profile , Vanguard Personalized Indexing Management , Bard Financial Services , Get Rating , Financial Services , Financial Advisors , Asset Management , Personalized Indexing Management , Exchange Commission , Ionis Core , Ionis Pharmaceuticals Daily , Nasdaq Ions ,